Attached files
| file | filename |
|---|---|
| EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - GT Biopharma, Inc. | gtbp_ex321.htm |
| EX-10.24 - CONSULTANT AGREEMENT - GT Biopharma, Inc. | gtbp_ex1024.htm |
| EX-10.23 - BOARD SERVICE AGREEMENT - GT Biopharma, Inc. | gtbp_ex1023.htm |
| EX-10.22 - BOARD SERVICE AGREEMENT - GT Biopharma, Inc. | gtbp_ex1022.htm |
| EX-10.21 - STEVE WELDON LETTER OF RESIGNATION - GT Biopharma, Inc. | gtbp_ex1021.htm |
| EX-10.20 - FORM OF SETTLEMENT NOTE - GT Biopharma, Inc. | gtbp_ex1020.htm |
| EX-10.19 - SETTLEMENT AGREEMENT - GT Biopharma, Inc. | gtbp_ex1019.htm |
| 10-Q - QUARTERLY REPORT - GT Biopharma, Inc. | gtbp_10q.htm |
Exhibit 31.1
CERTIFICATIONS
I, Anthony Cataldo, certify that:
|
2.
|
Based
on my knowledge, this report does not contain any untrue statement
of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the
period covered by this report;
|
|
3.
|
Based
on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in
this report;
|
|
4.
|
The
registrant’s other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and
internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have for
the registrant and have:
|
|
|
a)
|
Designed
such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to
ensure that material information relating to the
registrant, including
its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report
is being prepared;
|
|
|
b)
|
Designed
such internal control over financial reporting, or caused such
internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles;
|
|
|
c)
|
Evaluated
the effectiveness of the registrant’s disclosure controls and
procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the
end of the period covered by this report based on such evaluation;
and
|
|
|
d)
|
Disclosed
in this report any change in the registrant’s internal
control over financial reporting that occurred during the
registrant’s most recent fiscal quarter (the
registrant’s fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over
financial reporting; and
|
|
5.
|
The
registrant’s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant’s auditors and
the audit committee of the registrant’s board of directors
(or persons performing the equivalent functions):
|
|
|
a)
|
All
significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s
ability to record, process, summarize and report financial
information; and
|
|
|
b)
|
Any
fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant’s
internal control over financial reporting.
|
|
Date:
November 13, 2020
|
|
/s/ Anthony
Cataldo
|
|
|
|
|
Anthony
Cataldo
|
|
|
|
|
Chief
Executive Officer, Chief Financial Officer, Chairman, and
Director
|
|
|
|
|
|
|